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Abstract
Background: Different effectiveness profiles among antipsychotics may be a key point to optimize treatment in patients 
suffering a first episode of psychosis to impact on long-term outcome. The aim of this study is to compare the clinical 
effectiveness of olanzapine, risperidone, haloperidol, aripiprazole, ziprasidone, and quetiapine in the treatment of first 
episode of psychosis at 3-year follow-up.
Method: From February 2001 to January 2011, 2 phases of a prospective, randomized, open-label study were undertaken. 
A total of 376 first-episode drug-naïve patients were randomly assigned to olanzapine (n = 55), risperidone (n = 63), haloperidol 
(n = 56), aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 3 years. The primary effectiveness 
measure was all cause of treatment discontinuation. In addition, an analysis based on intention-to-treat principle was 
conducted in the analysis for clinical efficacy.
Results: The overall dropout rate at 3 years reached 20.75%. Treatment discontinuation rates were significantly different among 
treatment groups (olanzapine = 69.09, risperidone = 71.43, aripiprazole = 73.08%, ziprasidone = 79.03%, haloperidol = 89.28%, 
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and quetiapine = 95.53%) (χ2 = 79.86; P = .000). Statistically significant differences in terms of lack of efficacy, adherence, and 
tolerability were observed among treatment groups along the 3-year follow-up, determining significant differences in time to 
all-cause discontinuation (log-rank = 92.240; P = .000). Significant differences between treatments were found in the categories 
of sleepiness/sedation, increased sleep duration, akinesia, weight gain, ejaculatory dysfunction, extrapyramidal-symptoms, 
and amenorrhea.
Conclusions: Olanzapine, risperidone, and aripiprazole presented advantages for the first-line treatment of first episode of 
psychosis in terms of effectiveness. Identifying different discontinuation patterns may contribute to optimize treatment 
selection after first episode of psychosis.ClinicalTrials.gov Identifier: NCT02526030 https://clinicaltrials.gov/show/
NCT02526030
Keywords:  schizophrenia, antipsychotics, first-episode-psychosis
Introduction
Implementing the most suitable treatment strategies and 
making appropriate clinical decisions about individuals with a 
first episode of psychosis (FEP) is a complex and crucial task with 
relevant impact in illness outcome (Crespo-Facorro et al., 2016). 
Antipsychotics have demonstrated over the last 4 decades that 
they work both to treat acute psychotic episodes and to reduce 
relapse rates over the short to medium term (Correll et al., 2018). 
Prevention of recurrent episodes is likely to be critical to pre-
vent disease progression (Emsley et al., 2013; Pelayo-Terán et al., 
2017). Relapses involve an increased risk for a poorer and de-
layed response in the subsequent episode with higher treatment 
doses, potential side-effects emergence, and longer duration of 
active psychosis determining neurotoxicity (Pelayo-Terán et al., 
2018; Samara et al., 2015; Takeuchi et al., 2019). Nonadherence to 
medication seems to represent the highest risk for relapse after 
a FEP. Lack of efficacy, poor tolerability, and acceptability are the 
other main causes that increase the risk for discontinuation 
during early phases after a FEP. Hence, higher treatment discon-
tinuation rates are linked to higher relapse rates and a worsened 
prognosis (Leucht et  al., 2013). That is why FEP first-line anti-
psychotic choice is so critical. A recent meta-analysis focused on 
long-term patients with schizophrenia suggested that, although 
there are some significant differences in effectiveness, efficacy, 
and tolerability among second-generation antipsychotics (SGAs) 
in the long-term treatment of schizophrenia due to the limited 
number of head-to-head clinical trials available so far, the com-
parative effectiveness of some SGAs is unclear (Kishimoto et al., 
2019). Therefore, knowledge about the comparative clinical 
characteristics of antipsychotics in the long-term treatment (in 
which the magnitude of benefits and risks of medications may 
be different from acute phase treatment) of schizophrenia is im-
portant albeit insufficient so far (Correll and Hert, 2013).
Thus, with this pool analysis, comparing head-to-head 6 anti-
psychotics widely used in routine clinical settings, we aim to add 
detailed information on effectiveness, efficacy, and tolerability 
outcomes to contribute to further guide the evidence-based 
long-term treatment of patients with schizophrenia (Crespo-
Facorro et al., 2012; Gómez-Revuelta et al., 2018). This may lead 
to identify predictors of beneficial outcomes with specific anti-
psychotics, which would further enhance the ability to person-
alize treatments.
We hypothesize that differences regarding the efficacy, toler-
ability, and adherence would result in differential effectiveness 
to lead such a critical election as first antipsychotic choice may 
be for the outcome of FEP patients.
Experimental Procedures
Study Setting
Data for the present investigation were obtained from an on-
going 3-year longitudinal intervention program of first-episode 
psychosis called PAFIP (Programa de Atención a las Fases 
Iniciales de Psicosis) conducted at the outpatient clinic and the 
inpatient unit of the University Hospital Marqués de Valdecilla, 
Spain (Pelayo-Terán et  al., 2008). Conforming to international 
standards for research ethics, this program was approved by the 
local institutional review board. Patients meeting inclusion cri-
teria and their families provided written informed consent prior 
to their inclusion to the program.
Participants
From February 2001 to January 2011, all referrals to PAFIP 
were screened for patients who met the following criteria: (1) 
15–60 years old; (2) living in the catchment area; (3) experiencing 
their first episode of psychosis; (4) no prior treatment with anti-
psychotic medication or, if previously treated, a total lifetime 
of adequate antipsychotic treatment of less than 6 weeks; (5) 
DSM-IV criteria for brief psychotic disorder, schizophreniform 
disorder, schizophrenia, psychotic disorder not otherwise 
Significance Statement
Despite the fact that antipsychotics are recommended for the maintenance treatment in schizophrenia, comparative long-term 
effectiveness among antipsychotics is unclear, as long-term head-to-head comparisons among SGAs are limited in clinical prac-
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clear advantages for the first-line treatment of FEP. Multiple tolerability profiles and different efficacy measures were identified 
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specified, or schizoaffective disorder. Patients were excluded 
for any of the following reasons: (1) meeting DSM-IV criteria 
for drug dependence, (2) meeting DSM-IV criteria for mental re-
tardation, (3) having a history of neurological disease or head 
injury. The diagnoses were confirmed using the Structured 
Clinical Interview for DSM-IV (First et al., 2002) carried out by 
an experienced psychiatrist 6 months on from the baseline visit. 
Our operational definition for a “first episode of psychosis” in-
cluded individuals with a nonaffective psychosis (meeting the 
inclusion criteria defined above) regardless of the duration of 
untreated psychosis.
Study Design
Patients included in this study were assigned in 2 different al-
beit consecutive phases of the PAFIP (2001–2004 and 2005–2011), 
encompassing 2 randomized, flexible-dose, and open-label 
clinical trials. During the first phase, from February 2001 to 
September 2005, patients were randomly assigned to treatment 
with olanzapine, risperidone, or haloperidol. Consecutively, 
between October 2005 and January 2011, patients were ran-
domly assigned to treatment with aripiprazole, ziprasidone, or 
quetiapine.
We used a simple randomization procedure. An automated 
randomization list was drawn up. At study intake, all patients 
but 11 (2.92%) were antipsychotic naïve (mean duration of prior 
treatment = 2.75 weeks, SD = 1.8, range = 0.4–4.0). Before starting 
on the assigned drug, these participants underwent a 2- to 4-day 
washout period. Mean antipsychotic doses expressed as chlorpro-
mazine equivalents (CPZeq; mg/d) (Woods, 2003) were as follows: 
olanzapine 5–20 mg/d (100–400 CPZeq), risperidone 3–6 mg/d (150– 
300 CPZeq), haloperidol 3–9  mg/d (150–450 CPZeq), quetiapine 
100–600 mg/d (133.33–800 CPZeq), ziprasidone 40–160 mg/d (66.67–
266.67 CPZeq), and aripiprazole 5–30  mg/d (66,67–400 CPZeq). 
Rapid titration schedule (5 days), until optimal dose was reached, 
was used as a rule unless severe side effects occurred.
At the treating psychiatrist´s discretion, the dose and type of 
antipsychotic medication could be changed based on clinical ef-
ficacy and the profile of side effects during the follow-up period. 
Anticholinergic medication, lormetazepam, and clonazepam 
were permitted for clinical reasons. No anticholinergic agents 
were administered prophylactically. Antidepressants and mood 
stabilizers were permitted if clinically needed. The severity 
scale of the Clinical Global Impression (CGI) scale (Guy, 1976), 
the Brief Psychiatric Rating Scale (BPRS) (expanded version of 24 
items) (Overall and Gorham, 1962), the Scale for the Assessment 
of Positive symptoms (SAPS) (Andreasen, 1984), the Scale for 
the Assessment of Negative symptoms (SANS) (Andreasen, 
1989), the Calgary Depression Scale for Schizophrenia (CDSS) 
(Addington et  al., 1993), and the Young Mania Rating Scale 
(YMRS) (Young et al., 1978) were used to evaluate clinical symp-
tomatology. The scale of the Udvalg for Kliniske Undersogelser 
(UKU) (Committee of Clinical Trials) (Lingjærde et  al., 1987), 
the Simpson-Angus Rating Scale (SARS) (Simpson and Angus, 
1970), and the Barnes Akathisia Scale (BAS) (Barnes, 1989) were 
used to assess side effects. Clinical assessments and measure-
ments were completed at baseline, 3 weeks, 6 weeks, 3 months, 
6 months, 12 months, 18 months, 24 months, 30 months, and 
36 months. All patients included in the analysis had at least the 
baseline and 3-year assessments, and they were considered for 
drop-out in those cases in which they did not attend 2 consecu-
tive check-point assessments. The same trained psychiatrist 
(B.C.-F.) completed all clinical assessments.
Outcome Measures
Primary Outcome Measures: Effectiveness
The main outcome of effectiveness was the all-cause treat-
ment discontinuation rate, which is the percentage of all-cause 
discontinuation of the initially assigned treatment (patients 
who completed the 3-year follow-up assessment and their ini-
tial antipsychotic treatment were switched during follow-up) 
and the mean time to all-cause medication discontinu-
ation. Four reasons for the discontinuation were recorded: (1) 
nonsufficient or insufficient efficacy, (2) significant side effects, 
(3) nonadherence, and (4) other causes. Insufficient efficacy was 
established at the treating physician’s judgment only after at 
least 3 weeks of treatment. Adherence to antipsychotic drugs 
was assessed by the information obtained from patients, close 
relatives, and staff (nurse, social worker, and psychiatrists) in-
volved in the follow-up. According to previous definition (Gómez-
Revuelta et al., 2018), patients were consensually dichotomized 
into having a good (defined as patients regularly taking at least 
90% of prescribed medication) and a poor adherence (medium 
or poor compliance). If more than 1 reason for discontinuation 
was present, the most important reason according to the above 
ranking was selected.
Secondary Outcome Measures: Efficacy and Safety
The efficacy outcomes were the mean change from baseline to 
3 years in BPRS, SAPS, and SANS total scores. Additional ana-
lyses included changes from baseline to 3 years in CGI, YMRS, 
and CDSS total scores. Patients were defined as responders to 
the optimum dose of antipsychotic if they had a ≥50% reduction 
of BPRS total score and a CGI severity-score ≤4 after 6 months 
since the beginning of the treatment. Side effects were evalu-
ated using the UKU side effects rating scale. Only side effects 
rated as moderate or severe and with a possible causal rela-
tionship to medication were recorded. Treatment-emergent 
akathisia and extrapyramidal symptoms were assessed using 
BAS and SARS scales.
Statistical Analyses
All data were tested for normality (using Kolmogorov-Smirnov 
test) and equality of variances (using Levene test). To ensure 
group comparability, baseline sociodemographic and clinical 
characteristics were tested by 1-way ANOVA or Kruskal-Wallis 
tests for continuous variables or by chi-squared tests for quali-
tative variables.
Kaplan-Meier survival curves and log-rank tests were used to 
assess time to all-cause medication discontinuation. Concerning 
these 2 analyses, patients were followed-up from the inclusion 
in the study until discontinuation of the initial treatment or cen-
soring. Survival time could be censored by the end of the obser-
vation period or by lost to follow-up.
For efficacy and safety measures, we performed both 
intention-to-treat analyses and per-protocol analyses. 
Differences between groups in the degree of change in clinical 
scores from baseline were evaluated with ANCOVA after base-
line scores were controlled. Finally, comparisons of the discon-
tinuation rates and the prevalence of side effects as well as the 
use of concomitant treatment between the 6 antipsychotics 
were carried out, performing chi-squared tests with Bonferroni 
correction for multiple comparisons when necessary.
STATA 15.1 was used for statistical analysis. Statistical tests 
were 2-tailed with a 95% confidence interval.
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Results
Of 406 individuals who were initially randomized to treatments, 
30 were finally removed from the dataset after verifying they 
did not fully meet inclusion criteria or removed proper written 
consent during the first week. Thus, the final sample consisted 
of 376 participants who were randomly assigned to 6 different 
antipsychotic treatments: 55 patients were randomly assigned 
to the olanzapine group, 63 to the risperidone group, 56 to the 
haloperidol group, 78 patients to the aripiprazole group, 62 were 
assigned to the quetiapine group, and 62 to the ziprasidone 
group (Figure 1). The overall dropout rate at 3 years was small 
(n = 78; 20.74%); 46 patients dropped out prior to treatment 
discontinuation and were censored for the survival analysis 
(5-haloperidol, 9-olanzapine, 10-risperidone, 9-aripiprazole, 
8-quetiapine, and 5- ziprasidone). Our study gave the option to 
patients who were stable (symptom free for at least 12 months) 
and functionally recovered (at least 6 months under sustained 
recovery) to discontinue use of antipsychotic treatment while 
continuing to be followed-up by study clinicians (Mayoral-van 
Son et al., 2016). Seventeen patients entered this antipsychotic 
discontinuation program and were carefully monitored during 
the following 18 months after discontinuation. Sixteen of these 
17 patients completed the 3-year assessment but were censored 
for the primary outcome analysis.
Five patients committed suicide during the 3-year follow-up 
(1 olanzapine, 1 aripiprazole, 1 ziprasidone, and 2 quetiapine) 
and there was 1 sudden death (aripiprazole; heart attack).
All but 11 individuals in the study were white Caucasian (no 
significant differences were found between treatment groups 
after Bonferroni correction). Instead, we found significant differ-
ences between treatment groups concerning some demographic 
variables (living with parents, single status, age at admission, 
age at FEP onset, and duration of illness), which were adjusted 
by Bonferroni correction later. Demographic and clinical charac-
teristics of patients are shown in Table 1.
Primary Outcome Measures
Treatment Discontinuation Rate and Time to Discontinuation
An impressive 79.25 % of the initial sample completed follow-up. 
Overall treatment discontinuation rate (the cumulative per-
centage of discontinuation considering the 6 arms of the study) 
also reached 79.25% by 3  years, which is in line with other 
medium and long-term (52 weeks or more) follow-up studies 
(Lieberman et  al., 2005; Kahn et  al., 2008a). It differed signifi-
cantly between treatment groups (χ 2 = 79.860; P = .000) (Table 2). 
Patients on quetiapine showed a higher (95.16 %) treatment dis-
continuation rate than those on olanzapine (69.09%), risperidone 
(71.43%), aripiprazole (73.08 %), ziprasidone (79.03 %), or halo-
peridol (89.28%). The mean time (days) until discontinuation was 
855 days for olanzapine, 786 days for risperidone, 452 days for 
aripiprazole, 295 days for haloperidol, 251 days for ziprasidone, 
and 60 days for quetiapine. There was a significant difference be-
tween groups (log rank = 90.240; P = .000) (see Figure 2). Log-rank 
pairwise comparisons showed no statistical differences between 
Figure 1. Consort flow chart.
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olanzapine, risperidone, and aripiprazole. However, results dif-
fered significantly favoring any antipsychotic when compared 
with quetiapine: aripiprazole (χ 2 = 28.95; P  <  .001), ziprasidone 
(χ 2 = 14.29; P  <  .001), olanzapine (χ 2 = 45.56; P = .156), haloperidol 
(χ 2 = 18.84; P  <  .001), and risperidone (χ 2 = 46.52; P  <  .001). Results 
also highlighted higher effectiveness of risperidone (χ 2 = 9.44; 
P = .002) and aripiprazole (χ 2 = 7.657; P = .022) over haloperidol. 
Olanzapine also took significant advantage over haloperidol 
(χ 2 = 11.23; P = .001) and ziprasidone (χ 2 = 8.81; P = .003). We only 
found a trend towards nondiscontinuation favoring aripiprazole 
and risperidone over ziprasidone and no differences were 
found between ziprasidone and haloperidol. Non- or insuffi-
cient efficacy in the group of quetiapine was the main reason 
for discontinuation rate differences (χ 2 = 87.43; P = .000). Patients 
under quetiapine treatment were significantly more likely to 
discontinue due to non- or insufficient efficacy compared with 
aripiprazole (χ 2 = 32.15; P = .000), ziprasidone (χ 2 = 19.35; P = .000), 
olanzapine (χ 2 = 39.91; P = .000), risperidone (χ 2 = 41.17; P = .000), 
or haloperidol patients (χ 2 = 27.83; P = .000). No significant dif-
ferences were found between the remaining treatment groups. 
Mean (SD) doses (adjusted by chlorpromazine equivalents) prior 
to discontinuation due to non- or insufficient efficacy were 
aripiprazole-520 CPZeq (SD = 131.7), ziprasidone-386.5 CPZeq 
(SD = 149.5), haloperidol-351.8 CPZeq (SD = 164.9), olanzapine-510 
CPZeq (SD = 292.4), risperidone-550 CPZeq (SD = 229.1), and 
quetiapine-586.2 CPZeq (SD = 251.1). Analysis of treatment dis-
continuation due to side effects revealed significant differ-
ences between groups (quetiapine 12.9%, ziprasidone 37.1%, 
risperidone 31.7%, olanzapine 14.5%, haloperidol 31.1%, and 
aripiprazole 12.82 %; χ 2 = 19.800; P = .001). Patients on ziprasidone 
discontinued treatment due to side effects significantly more 
frequently than those on aripiprazole (χ² = 11.490; P = .001), 
olanzapine (χ² = 12.400; P = .000), or quetiapine (χ² = 9.677; P = .006). 
We did not find significant differences in the direct comparisons 
between the remaining groups. Finally, there was a remarkable 
difference in terms of treatment adherence as individuals in the 
risperidone group showed better adherence than those individ-
uals in the aripiprazole (χ² = 12.13; P = .001), quetiapine (χ² = 19.43; 
P = .000), and haloperidol groups (χ² = 10.59; P = .001); aripiprazole 
patients also demonstrated worse adherence than those under 
treatment with ziprasidone (χ² = 8.45; P = .003). Mean chlorpro-
mazine equivalent daily doses at 3  years were: aripiprazole 
16.3 mg = 216.8 (SD = 164.1) CPZeq; ziprasidone 121.3 mg = 202.2 
(SD = 136.5) CPZeq; quetiapine 195.9 mg = 261.1 (SD = 136.5) CPZeq; 
risperidone 2.9 mg = 145 (95) (SD = 136.5) CPZeq; olanzapine 8.74 
mg = 174.8 (SD = 92) CPZeq; and haloperidol 3.2 mg = 160 (SD = 60) 
CPZeq. No significant differences were observed (P = .279).
Secondary Outcome Measures
Clinical Efficacy
ANCOVA analyses showed multiple differences (Table 3) in the 
changes of the total scores of the clinical scales between treat-
ments after controlling by baseline measurements except for the 
SANS score (P = .265) and the negative dimension score (P = .314). 
Thereby, significant differences on clinical scales showed CGI 
improvement: significantly larger for aripiprazole vs haloperidol 
and ziprasidone vs haloperidol, and olanzapine; SAPS score: 
olanzapine improvement significantly lower compared with 
aripiprazole and ziprasidone; positive dimension: aripiprazole 
and ziprasidone scores were significantly lower than those pro-
ceeding from haloperidol and olanzapine patients; disorganized 
dimension: patients on aripiprazole, quetiapine, and ziprasidone 
got significant larger improvements than olanzapine patients; 
CDSS score: ziprasidone and quetiapine patients got signifi-
cant improvements in depressive symptoms compared with 
haloperidol patients; YMRS score: significant improvement 
for aripiprazole compared with olanzapine. Per protocol ana-
lyses solely unveiled significant differences concerning CGI 
(P = .008) and YMRS (P = .001) baseline scores. Bonferroni post-
hoc analyses showed significantly higher baseline scores for 
aripiprazole compared with olanzapine and risperidone for both 
clinical scales (data available upon request).
Safety
Adverse Events
Intention-to-treat analyses of moderate and severe side ef-
fects that were frequent (in at least 5% of patients in any of 
the treatment groups) are displayed in Table 4. Significant dif-
ferences between treatments were found in the categories of 
sleepiness/sedation, increased sleep duration, akinesia, weight 
gain, ejaculatory dysfunction, and amenorrhea. After adjust-
ment by Bonferroni correction, aripiprazole was shown to cause 
less increased sleep duration than quetiapine (P = .015) and 
ziprasidone (P = .05) and risperidone was also less likely to do 
so than olanzapine, quetiapine, haloperidol, and ziprasidone 
Figure 2. Kaplan-Meyer survival graph: any cause discontinuation.














(n = 376)  
 Total % Total % Total % Total % Total % Total % Total % χ² P
Any cause 
discontinuation
57 73.08 45 71.43 38 69.09 59 95.53 49 79.03 50 89.28 298 79.25 79.86 .000
No efficacy 12 15.38 9 14.28 6 10.91 31 50,0 13 20.97 11 19.64 82 21.81 87.43 .000
No adherence 26 33.3 6 9.53 15 27.27 12 19.3 8 12.9 16 28.57 83 22.07 25.87 .000
Side effects 10 12.83 20 31.75 8 14.55 8 12.9 23 37.1 18 32.14 87 23.14 19.80 .001
Dropout 9 11.54 10 15.87 9 16.36 8 13.33 5 8.06 5 8.93 46 12.23 15.13 .010
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(all P < .05). Quetiapine was associated with increased somno-
lence compared with aripiprazole (P = .034), but amenorrhea 
was significantly less likely to emerge in this group compared 
with haloperidol (P = .037) and risperidone (P = .022). Risperidone 
produced an greater frequency of ejaculatory dysfunction than 
aripiprazole (P = .034). Aripiprazole patients were more likely 
to suffer akinesia compared with olanzapine (P = .004) and 
ziprasidone patients (P = .033). Finally, olanzapine caused a sig-
nificantly higher weight gain rate than ziprasidone (P = .001). Per-
protocol analysis showed rather similar results (data available in 
supplementary Material). In this sense, there were only 3 side-
effect categories that showed statistically significant differences 
(weight gain, sialorrhea, and ejaculatory dysfunction). None of 
them resulted in statistical significance after post-hoc analyses.
Extrapyramidal Symptoms
Significant differences in the SARS total score changes at 
3 years between treatments were found (F = 13.441; P = .020). The 
percentage of patients with treatment-emergent extrapyram-
idal symptoms (EPS) was statistically different between treat-
ments (aripiprazole = 23.8%, ziprasidone = 23.5%, quetiapine 20%, 
risperidone 40%, olanzapine 30%, haloperidol 48.8%; χ 2 = 13.441; 
P = .020). Haloperidol supplied a significant burden of extrapyr-
amidal side effects compared with aripiprazole, quetiapine, and 
ziprasidone (all P´s < .05) and so did risperidone compared with 
quetiapine (P = .043). There was no significant difference be-
tween treatments in the severity of akathisia (BAS total score) 
(F = 0.939; P = .456). Although the difference did not reach signifi-
cance, more individuals in the aripiprazole (22.6 %), haloperidol 
(27.7%), and ziprasidone groups (32.7 %) experienced treatment 
emergent akathisia compared with the other groups (quetiapine 
17.8 %, olanzapine 4.7%, and risperidone 17.8%). These dif-
ferences were significant for the UKU scale akathisia item 
(χ² = 11.932; P = .036), but after Bonferroni correction only the dif-
ferences between ziprasidone and olanzapine groups remained 
significant (P = .001). Per protocol analyses showed no statistic-
ally significant differences.
Concomitant Medication Use
Significant differences were found between treatment groups re-
garding the use of benzodiazepines (χ² = 21.52, P = .001), hypnotics 
(χ² = 47.76, P = .004), and anticholinergics (χ² = 43.76, P = .004). After 
adjustment by Bonferroni correction, we found that the benzo-
diazepine use in the aripiprazole group was significantly higher 
than in the quetiapine, haloperidol, olanzapine, and risperidone 
groups (all P < .05); similarly, aripiprazole, quetiapine, and 
ziprasidone patients needed hypnotics more frequently than 
olanzapine, risperidone, and haloperidol patients (all P < .05 ex-
cept for the comparison between quetiapine and haloperidol). 
Almost one-half of the sample required treatment with anti-
cholinergics at any time of the follow-up. Olanzapine (27.27%) 
stood out for being the treatment group that least frequently 
needed this sort of treatment (Table 5).
Discussion
Our aim with this research was to supply information from our 
experience to guide the choice of the first-line treatment for an 
FEP. Results show remarkable effectiveness, efficacy, and safety 
differences between the 6 antipsychotics included in the study. 
We distinguished 2 treatment groups according to their effect-
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Given that almost all the SGAs have reduced risk of EPS and 
tardive dyskinesia than FGAs, not all lead to important weight 
gain, and many are now available both in oral and long-acting 
intramuscular forms, treatment with an SGA would be the first 
choice in most cases (Smith et al., 2019).
Primary Outcome Measures
Treatment Discontinuation Rate and Mean Time to 
Discontinuation
Different patterns for discontinuation emerged at different 
phases during follow-up. This circumstance may determine dif-
ferent intensity interventions focused on efficacy, compliance, 
and tolerability adapted to each specific phase of the follow-up: 
over one-half of the patients who discontinued treatment did 
so during the first year after the outbreak (52.68% by the end 
of 1 year), of whom 40.71% discontinued treatment due to lack 
of efficacy. This compelling information is remarkable in that 
mean-time until all-cause discontinuation was after more than 
2 years in the olanzapine and risperidone groups and slightly 
after 1 year in the aripiprazole group. Instead, mean time until 
all-cause discontinuation appeared for patients on quetiapine 
barely reached 2 months follow-up. Mean time until all-cause 
discontinuation occurred after half a year follow-up for pa-
tients on haloperidol and ziprasidone treatment. Side effects 
(36.3%) were the following cause for discontinuation during 
the first year of follow-up, while nonadherence (30.54%) was 
the main cause for discontinuation between 1- and 3-year 
follow-up. Concerning the all-cause discontinuation rate and 
the mean time to discontinuation variables, we may split the 
antipsychotic treatments used for this research into 2 dif-
ferent groups according to their performance on preventing pa-
tients from discontinuation due to any cause: a leading group 
composed by olanzapine, risperidone, and aripiprazole and 
an underperformer group, including ziprasidone, quetiapine, 
and haloperidol. Therefore, olanzapine, risperidone, and 
aripiprazole proved to be significantly superior to quetiapine 
and haloperidol. Meanwhile, though ziprasidone was su-
perior to quetiapine and haloperidol as well, it was signifi-
cantly defeated by olanzapine and both aripiprazole and 
risperidone showed a trend towards superiority compared with 
ziprasidone. There were no significant differences between 
olanzapine, risperidone, and aripiprazole concerning any-cause 
discontinuation risk and mean time to discontinuation, though 
olanzapine performed slightly better, especially in terms of 
mean time to discontinuation, which was almost 2-fold longer 
compared with aripiprazole. Regarding these data aripiprazole 
effectiveness approaches that for other well-stablished ef-
fective antipsychotics have not been seen in other effectiveness 
studies (Leucht et al., 2013). Higher risk of all-cause treatment 
discontinuation and shorter mean time to discontinuation in 
quetiapine patients had already been described during early 
phases of treatment (McEvoy et al., 2007); in our sample, 50% 
of patients on quetiapine discontinued treatment due to non- 
or insufficient efficacy. Effectiveness studies using standard 
dosage ranges pointed out that quetiapine may be less effective 
than some other widely used SGAs (Tiihonen et al., 2017) and 
FGAs (Vanasse et al., 2016). Our results are consistent with the 
notion that most of the patients who start quetiapine stop 
taking it within a few weeks (Asmal et  al., 2013). Inadequate 
and transient dopamine-2 receptor occupancy has been pro-
posed as a possible mechanism underlying quetiapine lack of 
efficacy. On the other hand, its weak dopamine antagonism al-
lows low maximal occupancy values and relatively little vari-
ability in occupancy values, suggesting that high doses of this 
antipsychotic are not likely to exceed thresholds of more than 
80% occupancy, indicative of D2-receptor–mediated side effects 
(Lako et al., 2013). This supports the idea that higher doses may 
be tolerable and more efficient (Wang et al., 2017). We did not 
find significant differences between groups concerning treat-
ment dosage adjusted by chlorpromazine equivalents prior 
to discontinuation due to non- or insufficient efficacy. The 
quetiapine group presented with the second highest relative 
dosage compared with the other groups. According to other re-
ports (Tiihonen et al., 2017), it is difficult to discern whether the 
poorer performance of quetiapine is due to the product itself 
or to nonoptimal dosage. The main reasons for discontinuation 
in the haloperidol group were nonadherence (28.57%) and side 
effects (32.14%). Ziprasidone (37.1%) and risperidone (31.75%) 
patients were also more likely to discontinue treatment due to 
side effects. Most discontinuations due to side effects accrued 
during the 1-year follow-up. This difficulty arose during anti-
psychotic titration in these groups, explaining why patients 
on ziprasidone and haloperidol tolerated lower relative doses 
than the remaining quartet. According to these results, EPS, 
sexual adverse events, and somnolence (the most frequently 
reported secondary effects for discontinuation for risperidone, 
ziprasidone, and haloperidol) seem to represent the worst 
tolerated side effects. At the next stage of follow-up (from 
18 months on), we find an accumulation of treatment discon-
tinuation due to nonadherence basically affecting aripiprazole 
(33.3%) and olanzapine (27.27%) patients, for whom this was 
the main reason for discontinuation. The increase in discon-
tinuations due to nonadherence observed during the last year 
of follow-up in these groups might be explained by a natural 
decrease in the acceptability mediated by long-term exposure 
to treatment (Lieberman et al., 2005). Improvements in educa-
tional and other prophylactical measures like the use of long 
acting injectable formulations (Kishimoto et al., 2014; Jann and 
Penzak, 2018) may be of interest to deal with this preventable 
issue.














n = 376  
 n % n % n % n % n % n % n % χ² P
Benzodiacepines 72 92.31 42 66.67 38 69.09 54 87.1 45 72.58 40 71.43 291 77.39 21.523 .001
Hypnotics 53 67.95 20 31.75 15 27.27 42 67.74 36 58.86 20 35.71 186 49.47 47.765 .004
Antidepressants 24 30.77 16 25.40 15 27.27 26 42.94 16 25.81 11 19.64 108 28.72 8.356 .138
Anticholinergics 53 67.95 20 31.75 15 27.27 42 67.74 36 58.86 20 35.71 186 49.47 43.765 .004
Mood stabilizers 6 7.69 4 6.35 5 9.09 4 6.45 6 9.68 5 8.93 30 7.98 0.838 .975
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Secondary Outcome Measures
Efficacy
Our first-episode patients showed a decrease in total BPRS, SAPS, 
SANS, and CGI scores during the 3-year follow-up. Previous studies 
using pair-wise meta-analytic (Leucht et  al., 2009) comparisons 
have shown that SGAs like olanzapine, risperidone, amisulpride, or 
clozapine are more efficacious than FGAs. Our study shows clear 
advantages for SGAs except for quetiapine when compared with 
haloperidol. More recent network meta-analyses (Leucht et al., 2013) 
have been able to discern differences even between SGAs with the 
formerly mentioned SGAs leading the rankings in terms of efficacy 
for positive symptoms. Curiously, in our long-term study, we find 
that after controlling for baseline and sociodemographic measures, 
efficacy was superior for aripiprazole and ziprasidone compared 
with olanzapine for positive symptoms and CGI improvement after 
3 years. In previous short and mid-term studies involving the same 
sample, we did not find significant differences by 1 year (Crespo-
Facorro et  al., 2011, 2014). Clinical differences for positive symp-
toms seem to establish from that point on. Despite that apparent 
inferior efficacy, olanzapine offered the best performance regarding 
long-term discontinuation due to non- or insufficient efficacy. It 
might be explained by the fact that most of non- or insufficient effi-
cacy discontinuations accrue during the first 6 months of follow-up. 
No differences for remission or efficacy on positive symptoms were 
found during the 1-year follow-up period in our sample, but there 
was a decreasing trend towards inferiority for quetiapine. Optimal 
efficacy may critically impact long-term discontinuation outcome 
during this early phase. Nevertheless, long-term beneficious evo-
lution  concerning positive symptoms, especially for aripiprazole, 
should be acknowledged when choosing first-line treatment after 
FEP. Regarding depressive symptoms, quetiapine is acknowledged 
as a first-line treatment even in monotherapy in affective psych-
oses (Lindström et  al., 2017), but in several previous first-episode 
nonaffective psychoses studies, no significant differences between 
SGAs (including quetiapine) were found in reducing depressive 
symptoms after mid-term follow-up (Kahn et al., 2008b). No notable 
changes on negative symptoms were found with any of the 6 anti-
psychotics. Per protocol analysis did not show statistically signifi-
cant differences along follow-up.
Side Effects and Concomitant Medications
The differences in the percentage of patients with treatment-
emergent parkinsonism may be of clinical interest. A  higher 
percentage of extrapyramidal side effects was identified among 
patients treated with haloperidol and risperidone. As reported 
in previous studies, akathisia (Juncal-Ruiz et  al., 2017) repre-
sented a challenge among aripiprazole- and ziprasidone-treated 
individuals. These circumstances may partially explain that 
significantly more patients on aripiprazole and ziprasidone 
needed hypnotics, benzodiazepines, and anticholinergics to re-
lieve akathisia. In agreement with previous reports (Lee et al., 
2011; Vázquez-Bourgon et  al., 2018), no significant differences 
were found in the frequency of body weight increase between 
treatments (except for the comparison between ziprasidone 
and olanzapine), but a uniform trend to weight increase was 
appreciated with all of them. Intention-to-treat analysis re-
vealed that over 70% of the individuals on olanzapine showed 
a rapid body weight gain (Table 4). This should be regarded as 
a possible limitation for its first-line use as it contributes to a 
higher risk of metabolic issues (Smith et al., 2008). Interestingly, 
discontinuation due to severe or intolerable side effects was 
the main cause for discontinuation in our study but remained 
relatively low (23.14 %). Nevertheless, it was significant in the 
case of ziprasidone and haloperidol as was their main cause 
of discontinuation. Sleepiness/sedation was the most preva-
lent reported secondary effect for discontinuation in the case 
of ziprasidone (n = 8; 34.7%) and haloperidol despite low doses 
prior to discontinuation due to side effects (58.5 mg [SD = 34.3] 
and 1.8 mg [SD = 1.2], respectively). In the case of risperidone, we 
distinguished 2 patterns for discontinuation mediated by side 
effects; during the acute phase, most complaints focused on 
somnolence and EPS, while during the second half of follow-up, 
discontinuations were due to sexual complaints and weight 
gain. Olanzapine and quetiapine patients demonstrated lower 
secondary effects rates and the lowest discontinuation rates due 
to side effects. However, they are linked with more incidence of 
metabolic impairment (Davy et al., 2016) and a higher risk for 
health events (Vanasse et al., 2016). Thus, their use as first-line 
treatments should be considered cautiously. Per protocol ana-
lyses replicated the results for weight gain, showing a trend to-
wards significant weight gain in the olanzapine group consistent 
with extensive data available in research literature. Sialorrhea 
and ejaculatory dysfunction also presented statistically signifi-
cant results under per protocol analyses, but no significant dif-
ferences were identified between treatment groups.
Limitations and Strengths
Several limitations should be considered when interpreting our 
results. First, as a practical clinical trial, patients and observers 
(B.C.-F.) were not blinded to treatments in our study. The fact 
that the observers knew the medications prescribed may have 
involuntarily biased the outcomes. As a non-industry–funded 
study, the risk for systematic biased measuring study outcomes 
favoring any of the treatments is limited. Second, the mean 
doses of quetiapine used could be understood as somewhat low 
to treat first-episode individuals. However, controlled investiga-
tions have clearly confirmed that standard dosage range should 
be appropriate in everyday clinical practice (Johnsen et al., 2010). 
Optimal doses of antipsychotics within licensed range were 
chosen based on clinical efficacy and the presence of side effects 
and were adjusted according to the clinical situation of each pa-
tient. It is important to note that chlorpromazine equivalents 
are a proxy measure for the comparison of antipsychotic dosage 
in antipsychotic effectiveness studies. Thus, results emerging 
from these comparisons should be considered cautiously. Third, 
treatment adherence measures were collected from self-report 
and close observers (family members and social assistants) but 
not from antipsychotic blood levels. This could have an impact in 
the accuracy of discontinuation measures due to nonadherence.
On the other hand, this is one of the longest head-to-head 
antipsychotic effectiveness studies regarding follow-up (3 years). 
It was performed on a large (n = 376), well-characterized, and 
homogeneous sample, as most of patients (97.08%) were anti-
psychotic naïve prior to their inclusion and comprised some of 
the most widely used antipsychotic treatments.
Conclusions
Establishing risks and benefits of SGA treatments and identifying 
different discontinuation patterns may contribute to make better 
treatment selection after an FEP. In our research, 2 treatment 
groups were separated according to their performance: olanzapine, 
risperidone, and aripiprazole presented clear advantages for the 
first-line treatment of FEP in terms of effectiveness. In addition, 
guaranteeing a good adherence to effective antipsychotic treat-
ments is one of the priority challenges in the treatment of FEP 
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individuals to prevent a malignant course of the disease and has 
proven to be the main reason for discontinuation for the most ef-
fective treatments. Finally, balancing most frequent and severe 
side effects (metabolic risk and EPS) should be considered to fit the 
antipsychotic choice to each individual case.
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